Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Fermin Orgambide

Cybin's Major Depressive Disorder Treatment Trials Continue With Clinilabs Drug Development Corp

Three weeks after announcing the results of its preclinical trials for CYB003, Cybin (NYSE:CYBN) made public a partnership with Clinilabs Drug Development Corporation to take the proprietary drug to its next phase.

Clinilabs is to carry out Cybin’s Phase 1/2a clinical trial of CYB003 for treating Major Depressive Disorder (MDD). According to the company, this will be the first psilocybin analog to be evaluated in a Phase 1/2a trial for this particular disorder.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.